Allogene Therapeutics (ALLO) Operating Leases (2018 - 2026)

Allogene Therapeutics' Operating Leases history runs 9 years deep, the most recent figure standing at $81.1 million for Q1 2026.

• In Q1 2026, Operating Leases changed 0.3% year-over-year to $81.1 million; the TTM figure through Mar 2026 stood at $81.1 million (changed 0.3% YoY), while the FY2025 annual figure was $83.3 million, down 8.27% from the prior year.
• Operating Leases came in at $81.1 million for Q1 2026 at Allogene Therapeutics, down from $83.3 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $101.1 million in Q4 2022 to a low of $69.0 million in Q1 2022.
• A 5-year average of $87.2 million and a median of $88.3 million in 2023 frame the typical range for Operating Leases.
• Across the five-year window, Operating Leases surged 90.97% in 2022 and decreased 12.64% in 2023, its largest moves.
• Allogene Therapeutics' Operating Leases stood at $101.1 million in 2022, then decreased by 12.64% to $88.3 million in 2023, then climbed by 2.73% to $90.8 million in 2024, then declined by 8.27% to $83.3 million in 2025, then declined by 2.64% to $81.1 million in 2026.
• According to Business Quant data, Operating Leases over the past three periods registered $81.1 million, $83.3 million, and $77.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison